drugset / Trial / NCT06011772
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal cancer, when given in combination with standard therapies used in the treatment of advanced colorectal cancer.
Timeline
- Start
- 2023-12-18
- Primary completion
- 2026-02-05
- Completion
- 2026-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIMAvax-EGF | Vaccine | — | Intramuscular |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |
| Background | Irinotecan | Small molecule | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | Panitumumab | Monoclonal antibody | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |